{"preliminary_commentary":{"by_channel":{"x_thread":7,"youtube":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02179086\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[],"indication":"newly diagnosed glioblastoma","name":"NRG-BN001","nct_id":"NCT02179086","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nrg-bn001-nct02179086. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Group 1 = Photon IMRT centers. Participants undergo standard-dose postoperative photon radiotherapy using 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) administered once daily, 5 days per week. Treatment consists of 46 Gy in 23 fractions followed by a sequential boost to a total dose of 60 Gy in 30 fractions. Participants receive concurrent temozolomide orally once daily during radiotherapy for up to 49 days and adjuvant temozolomide orally once daily on days 1-5 of each 28-day cycle for up to 12 cycles in the absence of disease progression or unacceptable toxicity.","label":"Group 1 - Standard RT (Photon) (Arm A1)","type":"ACTIVE_COMPARATOR"},{"description":"Group 2 = Proton centers. Participants undergo the same standard-dose postoperative radiotherapy regimen described for Arm A1 but delivered using proton beam therapy. Participants receive concurrent and adjuvant temozolomide as described for Arm A1.","label":"Group 2 - Standard RT (Proton) (Arm A2)","type":"ACTIVE_COMPARATOR"},{"description":"Group 1 = Photon IMRT centers. Patients undergo dose-escalated and -intensified photon IMRT QD, 5 days a week for a total of 30 fractions.\n\nIn all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.","label":"Group 1 - Intensified RT (Photon) (Arm B)","type":"EXPERIMENTAL"},{"description":"Group 2 = Proton centers. Participants undergo the same radiotherapy regimen described for Arm B but delivered using proton beam therapy. The elective target volume receives 50 Gy(RBE) in 30 fractions, and the boost target volume receives 75 Gy(RBE) in 30 fractions. Participants receive concurrent and adjuvant temozolomide as described for Arm A1.","label":"Group 2 - Intensified RT (Proton) (Arm C)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2030-07-07","type":"ESTIMATED"},"conditions":["Glioblastoma"],"enrollment":{"count":624,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Photon Beam Radiation Therapy","otherNames":["External beam radiation therapy using photons (procedure)","Photon","Photon EBRT","Photon External Beam Radiotherapy","PHOTON Therapy","Radiation, Photon Beam"],"type":"RADIATION"},{"name":"Proton Beam Radiation Therapy","otherNames":["External beam radiation therapy protons (procedure)","External Beam Radiotherapy (protons)","PBRT","Proton","Proton EBRT","Proton External Beam Radiotherapy","Proton Radiation Therapy","PROTON Therapy","Radiation, Proton Beam"],"type":"RADIATION"},{"name":"Temozolomide","otherNames":["CCRG-81045","Gliotem","Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-","M & B 39831","M and B 39831","Methazolastone","RP-46161","SCH 52365","Temcad","Temizole","Temodal","Temodar","Temomedac","TMZ"],"type":"DRUG"}],"last_update":"2026-10-01","lead_sponsor":"NRG Oncology","official_title":"Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-07-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"Median Survival Time (Within Center Group)","timeFrame":"Randomization to death or last follow-up. Median follow-up at time of analysis was 16.2 months for Group 1 and 18.3 months for Group 2."}],"references":[],"start_date":{"date":"2014-12-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","url":"https://clinicaltrials.gov/study/NCT02179086"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nrg-bn001-nct02179086"}